Abiomed (BMV:ABMD *) - Stock Price, News & Analysis

Resumen acción ABMD *

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.

Acerca de la empresa

ABMD * fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 14.15%

Los beneficios aumentaron un 78.9% el año pasado

Análisis de riesgos

Se prevé que los beneficios disminuyan una media de 2.5% al año durante los próximos 3 años.

Acciones altamente ilíquidas

Grandes partidas extraordinarias que afectan a los resultados financieros

Competidores de Abiomed, Inc.

Sonova Holding

SWX:SOON

CHF15.4b

Olympus

TSE:7733

JP¥2.5t

Cochlear

ASX:COH

AU$21.0b

STERIS

NYSE:STE

US$20.7b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Abiomed
Historical stock prices
Current Share Price	US$7,565.00
52 Week High	US$7,565.00
52 Week Low	US$4,642.00
Beta	1.4
1 Month Change	4.12%
3 Month Change	n/a
1 Year Change	6.22%
3 Year Change	130.18%
5 Year Change	n/a
Change since IPO	46.84%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	ABMD *	MX Medical Equipment	Mercado MX
7D	0%	0%	0%
1Y	6.2%	0%	0%

Rentabilidad frente al sector: ABMD * superó al sector MX Medical Equipment , que obtuvo un rendimiento del -2.1% el año pasado.

Rentabilidad vs. Mercado: ABMD * superó al mercado MX, que obtuvo un rendimiento del 3.7% el año pasado.

Volatilidad de los precios

Is ABMD *'s price volatile compared to industry and market?
ABMD * volatility
ABMD * Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Precio estable de las acciones: ABMD *ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de ABMD * en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1981	2,003	Mike Minogue	www.abiomed.com

Resumen de fundamentos de Abiomed, Inc.

¿Cómo se comparan los beneficios e ingresos de Abiomed con su capitalización de mercado?
Estadísticas fundamentales de ABMD *
Capitalización bursátil	Mex$335.38b
Beneficios(TTM)	Mex$5.21b
Ingresos (TTM)	Mex$20.96b

64.4x

Ratio precio-beneficio (PE)

16.0x

Ratio precio-ventas (PS)

¿Está ABMD * sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ABMD *
Ingresos	US$1.07b
Coste de los ingresos	US$200.59m
Beneficio bruto	US$873.51m
Otros gastos	US$606.74m
Beneficios	US$266.76m

Últimos beneficios comunicados

Sep 30, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	5.91
Margen bruto	81.32%
Margen de beneficio neto	24.84%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado ABMD * a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción ABMD *

Recompensas

Análisis de riesgos

Competidores de Abiomed, Inc.

SWX:SOON

CHF15.4b

TSE:7733

JP¥2.5t

ASX:COH

AU$21.0b

NYSE:STE

US$20.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Abiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella-Supported HRPCI at TCT Symposium

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Recent updates

Abiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella-Supported HRPCI at TCT Symposium

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings released: EPS: US$1.20 (vs US$0.58 loss in 1Q 2022)

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Full year 2022 earnings released: EPS: US$3.00 (vs US$5.00 in FY 2021)

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold Mex$24m worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold Mex$105m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed Appoints of Myron L. Rolle to its Board of Directors

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

New 90-day high: Mex$6,952

Revenue beats expectations

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

Revenue beats expectations

New 90-day high: Mex$6,473

Abiomed, Inc. to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: Mex$6,240

New 90-day low: Mex$5,276

New 90-day low: Mex$5,302

Revenue beats expectations

Second quarter 2021 earnings released: EPS US$1.38

Abiomed Announces FDA Grants 510(k) Clearance for the Company's Innovative Cardiopulmonary Support Technology

Abiomed, Inc. Announces New Protect Iii Study Data That Demonstrates Reduced Rates of MACCE

Abiomed, Inc. to Report Q2, 2021 Results on Oct 29, 2020

Abiomed, Inc. Not to Provide Earnings Guidance for the Fiscal Year 2021

First quarter earnings released

Abiomed, Inc. (NasdaqGS:ABMD) acquired the remaining stake in Breethe, Inc.

Abiomed, Inc. to Report Q1, 2021 Results on Aug 06, 2020

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Abiomed, Inc.